Our Mission
OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment by developing monoclonal antibodies and other agents that target the biologic pathways critical to tumor initiating cells, also known as "cancer stem cells". We are leveraging our understanding of these tumor initiating cells to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer.
Latest News
- May 14, 2013OncoMed Pharmaceuticals Initiates Phase 1b/2 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5 (Anti-Notch2/3) in Small Cell Lung Cancer (SCLC) and Amends Phase1b/2 Pancreatic Cancer Trial
- April 9, 2013OncoMed Presents New Data in Six Anti-Cancer Stem Cell Programs at AACR
- April 2, 2013OncoMed To Present New Data in Six Anti-Cancer Stem Cell Programs at AACR
- March 7, 2013OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-52M51 (Anti-Notch1) in Solid Tumors

